Insider Selling: Artivion, Inc. (NYSE:AORT) Insider Sells 15,100 Shares of Stock

Artivion, Inc. (NYSE:AORT) insider John E. Davis sold 15,100 shares of Artivion stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $23.61, for a total transaction of $356,511.00. Following the transaction, the insider now directly owns 208,778 shares of the company’s stock, valued at approximately $4,929,248.58. This represents a 6.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Artivion Trading Up 0.4 %

Shares of AORT opened at $23.58 on Thursday. Artivion, Inc. has a 1-year low of $19.11 and a 1-year high of $32.33. The company has a 50-day moving average of $28.83 and a 200 day moving average of $27.77. The firm has a market capitalization of $991.37 million, a price-to-earnings ratio of -1,178.85 and a beta of 1.79. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The company had revenue of $97.31 million for the quarter, compared to the consensus estimate of $100.82 million. On average, research analysts expect that Artivion, Inc. will post 0.37 EPS for the current year.

Institutional Investors Weigh In On Artivion

Several large investors have recently modified their holdings of the business. Wellington Management Group LLP raised its holdings in shares of Artivion by 2.9% in the 3rd quarter. Wellington Management Group LLP now owns 1,656,264 shares of the company’s stock valued at $44,090,000 after purchasing an additional 46,267 shares in the last quarter. Wasatch Advisors LP raised its holdings in shares of Artivion by 27.7% in the 4th quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company’s stock valued at $29,791,000 after purchasing an additional 226,160 shares in the last quarter. Next Century Growth Investors LLC raised its holdings in shares of Artivion by 29.7% in the 4th quarter. Next Century Growth Investors LLC now owns 492,653 shares of the company’s stock valued at $14,085,000 after purchasing an additional 112,918 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Artivion by 10.0% in the 4th quarter. Northern Trust Corp now owns 463,250 shares of the company’s stock valued at $13,244,000 after purchasing an additional 42,170 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Artivion by 2.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 358,192 shares of the company’s stock valued at $10,241,000 after purchasing an additional 8,343 shares in the last quarter. Institutional investors own 86.37% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on AORT shares. Stifel Nicolaus dropped their price target on shares of Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a research note on Tuesday, February 25th. Needham & Company LLC dropped their price target on shares of Artivion from $34.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, February 25th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $33.00 price target on shares of Artivion in a research note on Tuesday, December 10th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $31.40.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.